EMAIL THIS PAGE TO A FRIEND

Toxicology and applied pharmacology

In vivo doses of butadiene epoxides as estimated from in vitro enzyme kinetics by using cob(I)alamin and measured hemoglobin adducts: an inter-species extrapolation approach.


PMID 25448046

Abstract

1,3-Butadiene (BD) is a rodent and human carcinogen. In the cancer tests, mice have been much more susceptible than rats with regard to BD-induced carcinogenicity. The species-differences are dependent on metabolic formation/disappearance of the genotoxic BD epoxy-metabolites that lead to variations in the respective in vivo doses, i.e. "area under the concentration-time curve" (AUC). Differences in AUC of the most gentoxic BD epoxy-metabolite, diepoxybutane (DEB), are considered important with regard to cancer susceptibility. The present work describes: the application of cob(I)alamin for accurate measurements of in vitro enzyme kinetic parameters associated with BD epoxy-metabolites in human, mouse and rat; the use of published data on hemoglobin (Hb) adduct levels of BD epoxides from BD exposure studies on the three species to calculate the corresponding AUCs in blood; and a parallelogram approach for extrapolation of AUC of DEB based on the in vitro metabolism studies and adduct data from in vivo measurements. The predicted value of AUC of DEB for humans from the parallelogram approach was 0.078 nM · h for 1 ppm · h of BD exposure compared to 0.023 nM · h/ppm · h as calculated from Hb adduct levels observed in occupational exposure. The corresponding values in nM · h/ppm · h were for mice 41 vs. 38 and for rats 1.26 vs. 1.37 from the parallelogram approach vs. experimental exposures, respectively, showing a good agreement. This quantitative inter-species extrapolation approach will be further explored for the clarification of metabolic rates/pharmacokinetics and the AUC of other genotoxic electrophilic compounds/metabolites, and has a potential to reduce and refine animal experiments.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

56671
(±)-Propylene oxide, analytical standard
C3H6O
82320
(±)-Propylene oxide, puriss. p.a., ≥99.5% (GC)
C3H6O
110205
(±)-Propylene oxide, ReagentPlus®, ≥99%
C3H6O
488216
3,4-Dihydroxy-1-butene, ≥99%
C4H8O2
127574
3,4-Epoxy-1-butene, 98%
C4H6O
N5755
β-Nicotinamide adenine dinucleotide phosphate hydrate
C21H28N7O17P3 · xH2O
N8035
β-Nicotinamide adenine dinucleotide phosphate sodium salt, pkg of 5 mg (per vial)
C21H27N7NaO17P3
N8160
β-Nicotinamide adenine dinucleotide phosphate sodium salt, pkg of 10 mg (per vial)
C21H27N7NaO17P3
94640
DL-Valine, ReagentPlus®, ≥99.0% (NT)
C5H11NO2
W344400
DL-Valine, ≥97%
C5H11NO2
58221
ISA (ionic strength adjustment solution: 1 M KCl), 1 M KCl
ClK
60126
Potassium chloride, tested according to Ph Eur
ClK
PHR1329
Potassium Chloride, Pharmaceutical Secondary Standard; Certified Reference Material
ClK
60137 Potassium chloride solution, for Ag/AgCl electrodes, ~3 M KCl, saturated with silver chloride (~0.16 M AgCl)
ClK
60135
Potassium chloride solution, BioUltra, ~3 M in H2O
ClK
60134
Potassium chloride solution, conductance standard A acc. to ISO 7888, 0.1 M KCl
ClK
60136
Potassium chloride solution, conductance standard B acc. to ISO 7888, 0.01 M KCl
ClK
60138
Potassium chloride solution, conductance standard C acc. to ISO 7888, 0.001 M KCl
ClK
V0030000
Valine, European Pharmacopoeia (EP) Reference Standard
C5H11NO2
H7126
Vitamin B12a hydrochloride, analytical standard
C62H89CoN13O15P · HCl
95200
Vitamin B12a hydrochloride, ≥96% (UV), ≥96% (HPLC)
C62H89CoN13O15P · HCl